| 000 | 01682 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516212016.0 | ||
| 264 | 0 | _c20140723 | |
| 008 | 201407s 0 0 rus d | ||
| 022 | _a0022-9040 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aArslanbekova, S M | |
| 245 | 0 | 0 |
_a[Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. _h[electronic resource] |
| 260 |
_bKardiologiia _c2013 |
||
| 300 |
_a21-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticoagulants _xpharmacokinetics |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 |
_aBiotransformation _xgenetics |
| 650 | 0 | 4 |
_aCardiovascular Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Monitoring _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHeart Valve Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aHeart Valve Prosthesis Implantation _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xpharmacokinetics |
| 650 | 0 | 4 |
_aLosartan _xpharmacokinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aPostoperative Period |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacokinetics |
| 650 | 0 | 4 |
_aWarfarin _xpharmacokinetics |
| 700 | 1 | _aSychev, D A | |
| 700 | 1 | _aKazakov, R E | |
| 700 | 1 | _aSmirnov, V V | |
| 700 | 1 | _aKuznetsova, E V | |
| 700 | 1 | _aGolukhova, E Z | |
| 773 | 0 |
_tKardiologiia _gvol. 53 _gno. 12 _gp. 21-4 |
|
| 999 |
_c23799888 _d23799888 |
||